To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Boehringer Ingelheim and Sanofi Enter into Alliance
Boehringer Ingelheim and Sanofi have announced that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.
Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.
Under the terms of the agreement Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 2015.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
